Adverse Event Profiles of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Adenocarcinoma Lung Patients in North Sumatera Population

Moh. Ramadhani Soeroso; Noni Novisari Soeroso; Setia Putra Tarigan; Elisna Syahruddin

doi:10.3889/oamjms.2022.9235

Authors

Moh. Ramadhani Soeroso Department of Pulmonology and Respiratory Medicine, Dr. Pirngadi Regional General Hospital, Medan, Indonesia
Noni Novisari Soeroso Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Sumatera Utara, Universitas Sumatera Utara Hospital, Medan, Indonesia
Setia Putra Tarigan Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Sumatera Utara, Universitas Sumatera Utara Hospital, Medan, Indonesia
Elisna Syahruddin Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Indonesia, Persahabatan Hospital, Jakarta, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2022.9235

Keywords:

Adverse events, Epidermal growth factor receptor tyrosine kinase inhibitors, Non-small cell lung cancer, Adenocarcinoma

Abstract

BACKGROUND: In early 2000, a new targeted therapy was introduced and appeared to be a medical revolution due to the great emergence of procedural treatments in lung cancers. This new target therapy has been developed recently, which is also accompanied by the development of molecular markers as medical guidance.

AIM: This study aims to assess the side effect of the usage of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) on lung adenocarcinoma patients in North Sumatera.

METHODS: This study was a descriptive analysis study with consecutive sampling. Data was collected from the medical records of 50 pulmonary adenocarcinoma patients who have been treated by EGFR-TKI erlotinib and gefitinib. The statistical analysis was performed through SPSS software.

RESULTS: From this study, the majority of subjects were in the age range of 50–60 years old (24%), had no smoking history (52%), and were in Stage IVA (62%) at the time of diagnosis. Allele-specific polymerase chain reaction was performed and showed that exon 19 was found as the commonest mutations (62%). After using the first generation of EGFR-TKI including erlotinib and gefitinib, the majority of subjects experienced Grade I toxicities (46%) involved skin (acneiform).

CONCLUSION: The most common adverse event that is occurred in the cases was in skin disorders (72% of cases), which is particularly indicated by acne rash (46% of cases). The degree of toxicity during the medications was populously on degree 1 (46% of cases).

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Collisson EA, Campbell JD, Brooks AN, Berger AH, Lee W, Chmielecki J, et al. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543-50. https://doi.org/10.1038/nature13385 PMid:25079552 DOI: https://doi.org/10.1038/nature13385

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49. https://doi.org/10.3322/caac.21660 PMid:33538338 DOI: https://doi.org/10.3322/caac.21660

Lancet T. Lung cancer: A global scourge. Lancet. 2013;382(9893):659. https://doi.org/10.1016/S0140-6736(13)61759-6 PMid:23972796 DOI: https://doi.org/10.1016/S0140-6736(13)61759-6

Peng L, Qin BD, Xiao K, Xu S, Yang JS, Zang YS, et al. A meta-analysis comparing responses of Asian versus non-Asian cancer patients to PD-1 and PD-L1 inhibitor-based therapy. Oncoimmunology. 2020;9(1):1781333. https://doi.org/10.1080/2162402X.2020.1781333 PMid:32923143 DOI: https://doi.org/10.1080/2162402X.2020.1781333

Marino FZ, Bianco R, Accardo M, Ronchi A, Cozzolino I, Morgillo F, et al. Molecular heterogeneity in lung cancer: From mechanisms of origin to clinical implications. Int J Med Sci. 2019;16(7):981-9. https://doi.org/10.7150/ijms.34739 PMid:31341411 DOI: https://doi.org/10.7150/ijms.34739

Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380-8. https://doi.org/10.1056/NEJMoa0909530 PMid:20573926 DOI: https://doi.org/10.1056/NEJMoa0909530

Lim CK, Wei YF, Tsai MS, Chen KY, Shih JY, Yu CJ. Treatment effectiveness and tolerability of afatinib at different doses in patients with EGFR-mutated lung adenocarcinoma: How low can we go? Eur J Cancer. 2018;103(7):32-40. https://doi.org/10.1016/j.ejca.2018.07.128 PMid:30199768 DOI: https://doi.org/10.1016/j.ejca.2018.07.128

Ding PN, Lord SJ, Gebski V, Links M, Bray V, Gralla RJ, et al. Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: A meta-analysis of clinical trials of gefitinib, erlotinib, and afatinib in advanced EGFR-mutated non-small cell lung cancer. J Thorac Oncol. 2017;12(4):633-43. https://doi.org/10.1016/j.jtho.2016.11.2236 PMid:28007626 DOI: https://doi.org/10.1016/j.jtho.2016.11.2236

DeRouen MC, Hu L, McKinley M, Gali K, Patel M, Clarke C, et al. Incidence of lung cancer histologic cell-types according to neighborhood factors: A population-based study in California. PLoS One. 2018;13(5):e0197146. https://doi.org/10.1371/journal.pone.0197146 PMid:29791458 DOI: https://doi.org/10.1371/journal.pone.0197146

Soeroso NN, Zain-Hamid R, Sinaga BY, Sadewa AH, Syafiuddin T, Syahruddin E, et al. Genetic polymorphism of CYP2A6 and its relationship with nicotine metabolism in male bataknese smokers suffered from lung cancer in Indonesia. Open Access Maced J Med Sci. 2018;6(7):1199-205. https://doi.org/10.3889/oamjms.2018.259 PMid:30087722 DOI: https://doi.org/10.3889/oamjms.2018.259

Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst. 1999;91(14):1194-210. https://doi.org/10.1093/jnci/91.14.1194 PMid:10413421 DOI: https://doi.org/10.1093/jnci/91.14.1194

Lee SH, Kim WS, Choi YD, Seo JW, Han JH, Kim MJ, et al. Analysis of mutations in epidermal growth factor receptor gene in Korean patients with non-small cell lung cancer: Summary of a nationwide survey. J Pathol Transl Med. 2015;49(6):481-8. https://doi.org/10.4132/jptm.2015.09.14 PMid:26459407 DOI: https://doi.org/10.4132/jptm.2015.09.14

Syahruddin E, Wulandari L, Muktiati NS, Rima A, Soeroso N, Ermayanti S, et al. Uncommon EGFR mutations in cytological specimens of 1,874 newly diagnosed Indonesian lung cancer patients. Lung Cancer Targets Ther. 2018;9:25-34. https://doi.org/10.2147/LCTT.S154116 PMid:29615847 DOI: https://doi.org/10.2147/LCTT.S154116

Govindan R, Ding L, Griffith M, Subramanian J, Dees ND, Kanchi KL, et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell. 2012;150(6):1121-34. https://doi.org/10.1016/j.cell.2012.08.024 PMid:22980976 DOI: https://doi.org/10.1016/j.cell.2012.08.024

Elhidsi M, Andarini SL, Hudoyo A. Mia elhidsi: Profil mutasi epidermal growth factor receptor pasien adenokarsinoma paru usia muda profil mutasi epidermal growth factor receptor pasien adenokarsinoma paru usia muda proportion and profile of epidermal growth factor receptor mutation in young lung adenocarcinoma. J Respir Indo. 2016;36(4):244-8.

Melosky B, Burkes R, Rayson D, Alcindor T, Shear N, Lacouture M. Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr Oncol. 2009;16(1):14-24. DOI: https://doi.org/10.3747/co.v16i1.361

Yoshida T, Yamada K, Azuma K, Kawahara A, Abe H, Hattori S, et al. Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: A retrospective analysis. Med Oncol 2013;30(1):349. DOI: https://doi.org/10.1007/s12032-012-0349-y

Yang Z, Hackshaw A, Feng Q, Fu X, Zhang Y, Mao C, et al. Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis. Int J Cancer. 2017;140(12):2805-19. https://doi.org/10.1002/ijc.30691 PMid:28295308 DOI: https://doi.org/10.1002/ijc.30691